

10/560503
IAP6 Rec'd PCT/PTO 13 DEC 2005
ATTORNEY DOCKET: 58778.000006

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application Number	:	TBA	Confirmation No.:	TBA
First Named Inventor	:	INOUE et al.		
Filed	:	December 13, 2005		
Title	:	IMIDAZOTRIAZINONE DERIVATIVES AS PDE 7 INHIBITORS		
TC/Art Unit	:	TBA		
Examiner:	:	TBA		
Docket No.	:	58778.000006		
Customer No.	:	21967		

INFORMATION DISCLOSURE STATEMENT

MAIL STOP PCT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. §§ 1.97 and 1.98, and in compliance with the duty of disclosure set forth in 37 C.F.R. § 1.56, Applicants are submitting herewith copies of the references other than U.S. patents and U.S. patent publications listed on the attached Form PTO/SB/08A (modified) for consideration and request the documents cited therein be made of record by the U.S. Patent and Trademark Office in the above-captioned application.

Three of the documents listed on the attached Form PTO/SB/08A (modified) were cited by the European Patent Office in the International Search Report, mailed on September 13, 2004, for International Application No. PCT/JP2004/008642. A copy of the International Search Report is enclosed herein.

Consideration of the foregoing plus the prompt return of a copy of the enclosed Form PTO/SB/08A with the Examiner's initials in the left column in accordance with M.P.E.P. § 609 are respectfully requested.

Applicants respectfully point out that the submission of the listed documents in this Information Disclosure Statement is not an admission that they are prior art or that they are

10/560503

ATTORNEY DOCKET: 58778.000006

IAP6 Rec'd PCT/PTO 13 DEC 2005

material to patentability of any claims of the application. Also, the submission of this Information Disclosure Statement is not an indication that a search has been made by Applicants.

For the convenience of the Examiner in considering the cited documents, a copy of each of the cited documents other than U.S. patents and U.S. patent publications is enclosed with this communication. In considering the cited documents, it may be noted by the Examiner that certain of the documents may contain markings, underlinings, and/or other notations. These markings, underlinings, and/or other notations are not to be construed as drawing the Examiner's attention either to selected parts or away from other parts of the cited documents. Any such markings were either present on the copies of the cited documents obtained by the associated individuals, or were made thereon during the study of the documents by the associated individuals.

In accordance with 37 C.F.R. § 1.97(b), this Information Disclosure Statement is believed to be submitted prior to issuance of a first Office Action. Therefore, it is respectfully submitted that no fee is required for consideration of this information. However, in the event any fee is deemed necessary, the Commissioner is authorized to charge the undersigned's Deposit Account No. 50-0206.

Respectfully submitted,

HUNTON & WILLIAMS LLP

Dated: December 13, 2005

By: Alexander H. Spiegler
Robert M. Schulman
Registration No. 31,196

Alexander H. Spiegler
Registration No. 56,625

Hunton & Williams LLP
Intellectual Property Department
1900 K Street, N.W.
Suite 1200
Washington, DC 20006
(202) 955-1500 (telephone)
(202) 778-2201 (facsimile)
RMS/AHS:sac

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Application Number	To be assigned 560503
Filing Date	December 13, 2005
First Named Inventor	INOUE et al.
Art Unit	To be assigned
Examiner Name	To be assigned

Sheet	1 of 4	Attorney Docket Number	58778.000006
-------	--------	------------------------	--------------

U.S. PATENT DOCUMENTS

*Examiner Initials	Cite No.	DOCUMENT NUMBER Number - Kind Code (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1.	US- 6,613,778	09-02-2003	Eggenweiler et al.	
	2.	US- 6,627,651	09-30-2003	Shiraishi et al.	
	3.	US- 6,737,436	05-18-2004	Eggenweiler et al.	
	4.	US- 6,476,029	11-05-2002	Niewohner, et al.	
	5.	US- 6,362,178	03-26-2002	Niewohner, et al.	
	6.	US- 2002/0198377	12-26-2002	Niewohner, et al.	
	7.	US- 2004/0097498	05-20-2004	Niewohner, et al.	
	8.	US- 2004/0138279	07-15-2004	Eggenweiler et al.	
	9.	US- 2005/0195210	09-08-2005	Demers, et al.	
	10.	US- 2005/0043303	02-24-2005	Niewohner	
	11.	US- 2005/0009822	01-13-2005	Niewohner, et al.	
		US-			

EXAMINER SIGNATURE

DATE CONSIDERED

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute for form 1449/PTO				Application Number	<i>To be assigned</i> 107560503			
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Filing Date	December 13, 2005			
				First Named Inventor	INOUE et al.			
				Art Unit	<i>To be assigned</i>			
				Examiner Name	<i>To be assigned</i>			
Sheet	2 of 4			Attorney Docket Number	58778.000006			
FOREIGN PATENT DOCUMENTS								
*Examiner Initial	Cite No.	FOREIGN PATENT DOCUMENT		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	TRANSLATION	
		Country Code Number-Kind Code (if known)					YES	NO
12.	WO	03/097645	11-27-2003	Bayer Aktiengesellschaft			<input type="checkbox"/>	<input type="checkbox"/>
13.	WO	03/011262	02-13-2003	Bayer Aktiengesellschaft			<input type="checkbox"/>	<input type="checkbox"/>
14.	WO	02/098880	12-12-2002	Bayer Aktiengesellschaft			<input type="checkbox"/>	<input type="checkbox"/>
15.	WO	01/34601	05-17-2001	Merck Patent GmbH			<input type="checkbox"/>	<input type="checkbox"/>
16.	WO	00/68203	11-16-2000	Takeda Chcmical Industries, LTD.			<input type="checkbox"/>	<input type="checkbox"/>
17.	WO	01/32618	05-10-2001	Merck Patent GmbH			<input type="checkbox"/>	<input type="checkbox"/>
18.	DE	19950647	04-26-2001	Merck Patent GmbH			<input type="checkbox"/>	<input type="checkbox"/>
19.	WO	02/088080	11-07-2002	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
20.	WO	02/087513	11-07-2002	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
21.	WO	02/102315	12-27-2002	Bristol-Myers Squibb Co.			<input type="checkbox"/>	<input type="checkbox"/>
22.	WO	02/074754	09-26-2002	Warner-Lambert Co.			<input type="checkbox"/>	<input type="checkbox"/>
23.	WO	02/028847	4-11-2002	Warner-Lambert Co.			<input type="checkbox"/>	<input type="checkbox"/>
24.	WO	01/98274	12-27-2001	Celltech Chiroscience Ltd.			<input type="checkbox"/>	<input type="checkbox"/>
25.	WO	01/74786	10-11-2001	Darwin Discovery LTD.			<input type="checkbox"/>	<input type="checkbox"/>
26.	WO	02/40450	05-23-2002	BYK Gulden Lomberg Chemische Fabrik GmbH			<input type="checkbox"/>	<input type="checkbox"/>
27.	WO	01/47928	07-05-2001	Bayer Aktiengesellschaft			<input type="checkbox"/>	<input type="checkbox"/>
28.	WO	02/098879	12-12-2002	Bayer Aktiengesellschaft			<input type="checkbox"/>	<input type="checkbox"/>
29.	WO	02/098873	12-12-2002	Bayer Aktiengesellschaft			<input type="checkbox"/>	<input type="checkbox"/>
30.	WO	02/079203	10-10-2002	Pfizer Limited			<input type="checkbox"/>	<input type="checkbox"/>
EXAMINER SIGNATURE				DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.								

Substitute for form 1449/PTO		Application Number	<i>To be assigned</i> 10/1560503	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>		Filing Date	December 13, 2005	
		First Named Inventor	INOUE et al.	
		Art Unit	<i>To be assigned</i>	
		Examiner Name	<i>To be assigned</i>	
Sheet	4 of 4	Attorney Docket Number	58778.000006	
OTHER DOCUMENTS - NON-PATENT LITERATURE DOCUMENTS				
*Examiner Initials	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published		TRANSLATION
	39.	Barnes et al. "Synthesis and Structure-Activity Relationships of Guanine Analogues as Phosphodiesterase 7 (PDE7) Inhibitors." Bioorg. Med. Chem. Lett. (2001), Vol. 11, pgs. 1081-1083.		<input type="checkbox"/> <input type="checkbox"/>
	40.	Martinez et al. "Benzyl Derivatives of 2,1,3-Benzo- and Benzothieno[3,2-a]thiadiazine 2,2-Dioxides: First Phosphodiesterase 7 Inhibitors." J. Med. Chem. (2000), Vol. 43, pgs. 683-689.		<input type="checkbox"/> <input type="checkbox"/>
	41.	Castro et al. "CoMFA of benzyl derivatives of 2,1,3-benzo and benzothieno[3,2-a]thiadiazine 2,2-dioxides: clues for the design of phosphodiesterase 7 inhibitors." Eur. J. Med. Chem. (2001), Vol. 36, pgs. 333-338.		<input type="checkbox"/> <input type="checkbox"/>
EXAMINER SIGNATURE		DATE CONSIDERED		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.